Human pharmacokinetics of orally administered strontium. 1990

O R Leeuwenkamp, and W J van der Vijgh, and B C Hüsken, and P Lips, and J C Netelenbos
Department of Internal Medicine, Free University Hospital, Amsterdam, The Netherlands.

Pharmacokinetics of orally administered SrCl2 (2.5 mmol) were studied in six healthy male volunteers. In the overall plasma concentration time (C-t) curves, two absorption phases were observed due to two dominant intestinal absorption loci. A method was devised to obtain separately the plasma C-t curves associated with each of the two absorption loci (curve 1 and curve 2). These curves and the overall plasma C-t curve were analyzed with a nonlinear estimation program (PCNONLIN). Pharmacokinetic parameters (mean +/- SD, n = 6) calculated from the overall curve were as follows: peak plasma concentration (Cmax) 3.55 +/- 1.22 micrograms/ml and area under the plasma C-t curve (AUC affinity) 9138 +/- 1930 micrograms.min/ml. The pharmacokinetic parameters calculated from curve 1 were as follows: terminal plasma elimination half-life time 47.3 +/- 7.9 hour, the plasma elimination half-life time of the preceding phase 5.2 +/- 3.3 hour, Cmax 1 3.09 +/- 0.95 micrograms/ml, the first-order absorption rate constant for absorption locus 1 (Ka,1) 5.7 +/- 1.2 * 10(-2) minute-1 and the time lag (tlag,1) 11.7 +/- 7.9 minute. In three of the subjects the pharmacokinetic parameters of absorption locus 2 could be evaluated: Ka,2 = 4.6 +/- 0.4 * 10(-2) minute-1, tlag,2 = 77.3 +/- 4.0 minute, tmax,2 = 153 +/- 16 minute, Cmax,2 = 0.9 +/- 0.4 micrograms/ml and AUC 2 affinity = 1204 +/- 565 micrograms. minute/ml. and AUC2 affinity = 0.14, indicating that 14% of the absorbed dose was absorbed via the second locus.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013324 Strontium An element of the alkaline earth family of metals. It has the atomic symbol Sr, atomic number 38, and atomic weight 87.62.

Related Publications

O R Leeuwenkamp, and W J van der Vijgh, and B C Hüsken, and P Lips, and J C Netelenbos
December 1996, Annals of the New York Academy of Sciences,
O R Leeuwenkamp, and W J van der Vijgh, and B C Hüsken, and P Lips, and J C Netelenbos
July 1989, American journal of obstetrics and gynecology,
O R Leeuwenkamp, and W J van der Vijgh, and B C Hüsken, and P Lips, and J C Netelenbos
September 1979, American journal of hospital pharmacy,
O R Leeuwenkamp, and W J van der Vijgh, and B C Hüsken, and P Lips, and J C Netelenbos
January 2000, Annals of the New York Academy of Sciences,
O R Leeuwenkamp, and W J van der Vijgh, and B C Hüsken, and P Lips, and J C Netelenbos
February 1974, Clinical pharmacology and therapeutics,
O R Leeuwenkamp, and W J van der Vijgh, and B C Hüsken, and P Lips, and J C Netelenbos
January 1986, Journal of pharmaceutical sciences,
O R Leeuwenkamp, and W J van der Vijgh, and B C Hüsken, and P Lips, and J C Netelenbos
November 2000, Current pharmaceutical design,
O R Leeuwenkamp, and W J van der Vijgh, and B C Hüsken, and P Lips, and J C Netelenbos
September 1979, Journal of pharmaceutical sciences,
O R Leeuwenkamp, and W J van der Vijgh, and B C Hüsken, and P Lips, and J C Netelenbos
October 1974, Journal of pharmacokinetics and biopharmaceutics,
O R Leeuwenkamp, and W J van der Vijgh, and B C Hüsken, and P Lips, and J C Netelenbos
September 1999, International journal of dermatology,
Copied contents to your clipboard!